NeoGenomics, Inc. announced that as part of the on-going restructuring efforts, the executive position of President, Advanced Diagnostics is being eliminated and as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role and will no longer be a named executive officer. The effective date of the change is still being determined by the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.13 USD | -2.83% | +8.38% | -6.49% |
02/05 | North American Morning Briefing : Stock Futures -3- | DJ |
30/04 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.49% | 1.99B | |
-17.21% | 8.46B | |
+45.61% | 3.88B | |
-36.69% | 2.63B | |
-8.06% | 2.45B | |
-9.64% | 2.31B | |
-17.24% | 1.61B | |
-37.21% | 1.3B | |
+5.14% | 1.09B | |
-17.22% | 906M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics